Genetic variation, adipokines, and cardiometabolic disease

Sophia Metz, Lam Opal Huang, Tuomas O Kilpeläinen


Adipokines are adipocyte-secreted cell signalling proteins that travel to distant target organs and tissues, where they regulate a variety of biological actions implicated in cardiometabolic health. In the past decade, genome-wide association studies have identified multiple genetic variants associated with circulating levels of adipokines, providing new instruments for examining the role of adipokines in cardiometabolic pathologies. Currently, there is limited genetic evidence of causal relationships between adipokines and cardiometabolic disease, which is consistent with findings from randomized clinical trials that have thus far shown limited success for adipokine-based treatments in improving cardiometabolic health. Incorporating human genetic data in early phases of target selection is essential for enhancing the success of adipokine-based therapies for cardiometabolic disease.

TidsskriftCurrent Opinion in Pharmacology
Sider (fra-til)33-39
Antal sider7
StatusUdgivet - jun. 2020
Udgivet eksterntJa


Dyk ned i forskningsemnerne om 'Genetic variation, adipokines, and cardiometabolic disease'. Sammen danner de et unikt fingeraftryk.